S. Sait and S. Modak, "Anti-GD2 immunotherapy for neuro- blastoma," Expert Review of Anticancer Therapy, vol. 17, no. 10, pp. 889-904, 2017.Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017;17(10):889-904....
As its first cousin GD2, the OAcGD2 glycolipid is highly expressed at the cell membrane of orphan pediatric cancers (e.g. neuroblastoma), adult cancers (e.g. glioma, sarcoma, melanoma), and at the surface of cancer stem cells (e.g. in breast cancers) that are thought to be the chemo...
Here we report updated interim results from the first-in-human phase 1 evaluation of autologous NKTs co-expressing a GD2-specific CAR with interleukin 15 (IL15) (GD2-CAR.15) in 12 children with neuroblastoma (NB). The primary objectives were safety and determination of maximum tolerated dose...
The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal antibodies targeting GD2 have substantially improved outcomes for children with high-risk neuroblastoma. However, approximately 40% of patients with neuroblastoma still relapse, and anti-GD2 has not mediated significant clin...
免疫原 Neuroblastoma cell line LAN-1 应用 in vitro induction of apoptosis in GD2+ cells in vivo inhibition of GD2+ tumor cell growth 产品形式 PBS , pH 7.0 Contains no stabilizers or preservatives 内毒素水平 <2EU/mg (<0.002EU/...
1. M. Ozkaynak et al. “Phase I Study of Chimeric Human/Murine Anti–Ganglioside GD2 Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children’s Cancer Group Study” Journal ...
体外诱导 apoptosis in GD2+ cells, 体内 抑制 GD2+ tumor cell growth 免疫原 Neuroblastoma cell line LAN-1 来源宿主 产品说明书 反应性 见产品名称 保存建议 InVivoMAb 抗人神经节苷脂 GD2以蓝冰运输,储存方法:抗体溶液应在 4°C,以原液浓度储存。不要冻结。,如果按照建议储存,自接收之日起一年 ...
Despite improvements in survival of high-risk neuroblastoma patients after the introduction of anti-GD2 (disialoganglioside) immunotherapy, outcomes remain poor, and new therapies are needed to combat recurrent metastatic disease9. C–C motif chemokine ligand 2 (CCL2) or monocyte chemoattractant ...
Despite improvements in survival of high-risk neuroblastoma patients after the introduction of anti-GD2 (disialoganglioside) immunotherapy, outcomes remain poor, and new therapies are needed to combat recurrent metastatic disease9. C–C motif chemokine ligand 2 (CCL2) or monocyte chemoattractant protein...
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysisAndras Heczey, Amy N. Courtney, Antonino Montalbano, Simon Robinson, Ka Liu, Mingmei Li, Nisha Ghatwai, Olga Dakhova, Bin Liu, Tali Raveh-Sadka, Cynthia N. Chauvin-Fleurence, ...